INCYTE CORPORATION Finance Lease, Right-of-Use Asset, Amortization
INCYTE CORPORATION (INCY) reported Finance Lease, Right-of-Use Asset, Amortization of $4.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-10
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $700.00K, a 0.00% change year-over-year.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2021-09-30 was $700.00K, a 0.00% change year-over-year.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2021-06-30 was $700.00K, a 0.00% change year-over-year.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2021-03-31 was $600.00K, a 0.00% change year-over-year.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for fiscal 2025 was $4.50M, a 15.38% increase from fiscal 2024.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for fiscal 2024 was $3.90M, a 11.43% increase from fiscal 2023.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for fiscal 2023 was $3.50M, a 12.90% increase from fiscal 2022.
- INCYTE CORPORATION finance lease, right-of-use asset, amortization for fiscal 2022 was $3.10M, a 14.81% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.50M 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $3.90M 10-K · filed 2026-02-10 | |||
| 2023-12-31 | $3.50M 10-K · filed 2026-02-10 | |||
| 2022-12-31 | $3.10M 10-K · filed 2025-02-10 | |||
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $1.40M derived: sum of 2 quarters · filed 2024-02-13 | $2.10M derived: sum of 3 quarters · filed 2024-02-13 | $2.70M 10-K · filed 2024-02-13 |
| 2021-09-30 | $700.00K 10-Q · filed 2021-11-02 | $1.40M derived: sum of 2 quarters · filed 2021-11-02 | $2.00M 10-Q · filed 2021-11-02 | $2.70M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $700.00K 10-Q · filed 2021-08-03 | $1.30M 10-Q · filed 2021-08-03 | $2.00M derived: sum of 3 quarters · filed 2023-02-07 | $2.70M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | $600.00K 10-Q · filed 2021-05-04 | $1.30M derived: sum of 2 quarters · filed 2023-02-07 | $2.00M derived: sum of 3 quarters · filed 2023-02-07 | $2.70M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $1.40M derived: sum of 2 quarters · filed 2023-02-07 | $2.10M derived: sum of 3 quarters · filed 2023-02-07 | $2.60M 10-K · filed 2023-02-07 |
| 2020-09-30 | $700.00K 10-Q · filed 2021-11-02 | $1.40M derived: sum of 2 quarters · filed 2021-11-02 | $1.90M 10-Q · filed 2021-11-02 | $2.60M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $700.00K 10-Q · filed 2021-08-03 | $1.30M 10-Q · filed 2021-08-03 | $1.90M derived: sum of 3 quarters · filed 2021-08-03 | $2.60M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $600.00K 10-Q · filed 2021-05-04 | $1.20M derived: sum of 2 quarters · filed 2021-05-04 | $1.90M derived: sum of 3 quarters · filed 2021-05-04 | $2.10M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $1.30M derived: sum of 2 quarters · filed 2021-02-09 | $1.50M derived: sum of 3 quarters · filed 2021-02-09 | $1.70M 10-K · filed 2021-02-09 |
| 2019-09-30 | $700.00K 10-Q · filed 2020-11-05 | $900.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.10M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-04 | $400.00K 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |